Research monograph · triple glp-1/gip/glucagon receptor agonist peptide (ly3437943)
Metabolic Regulation Studies
This monograph collects what the published literature reports about GLP-3 RT — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. Single- and dual-agonist compounds are far better characterized; the research question specific to triple agonism is what the glucagon-receptor component contributes to metabolic endpoints on top of the other two.
For laboratory research use only — not for human or animal use
Mechanisms
Incretin Receptor Agonism
The GLP-1 receptor component is the best-characterized of the three, and the one shared with every single- and dual-agonist compound in this class. It is the reference arm against which the additional receptor activity is measured.
Gastric Inhibitory Signalling
The GIP receptor arm is the addition that distinguishes dual agonists from single. Published work examines whether GIP agonism, antagonism or neither best complements GLP-1 activity — a question the literature has not settled.
Glucagon Receptor Agonism
Glucagon receptor activity is what makes this compound a triple rather than dual agonist, and it is the least characterized of the three. Interest centers on hepatic energy expenditure — the endpoint the other two arms do not address.
Studied applications
Phase 2 work reported dose-dependent weight change over 48 weeks, with the highest dose arm producing the largest reported effect in this compound class to date.
Jastreboff et al. 2023
Examined in type 2 diabetes models against dual-agonist and placebo comparators, with HbA1c as the primary endpoint.
Rosenstock et al. 2023
The glucagon arm is studied for whether it raises energy expenditure rather than only reducing intake — the mechanistic question specific to triple agonism.
Coskun et al. 2022
Liver fat fraction has been measured as a secondary endpoint, on the basis that glucagon receptor activity acts directly on hepatocytes.
Sanyal et al. 2024
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
FAQ
GLP-3 RT is the research designation for LY3437943, a triple agonist engaging the GLP-1, GIP and glucagon receptors simultaneously. Single- and dual-agonist compounds are far better characterized; the research question specific to triple agonism is what the glucagon-receptor component contributes to metabolic endpoints on top of the other two.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. GLP-3 RT is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
